Therefore, this study aimed to investigate the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer with hormone receptor-positive and HER2-negative (ChiCTR2100046678). Here, NR4A1 is linked to breast cancer.